-Technology To Be Incorporated In Multiple SparingVision SAS Programs- ALACHUA, Fla. and CAMBRIDGE, Mass. , April 19, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene
- AGTC Transfers Clinical Trial Materials and Phase 1/2 Data To TeamedON - ROCKVILLE, Md. , April 13, 2021 (GLOBE NEWSWIRE) -- TeamedOn International, Inc. , a biotechnology company dedicated to advancing gene therapies for rare diseases, including ophthalmic indications, and Applied Genetic
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , March 31, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
-AGTC’s deep commitment to the patient voice drives solutions to support patient access to information and to improve the experience of patients participating in clinical trials- GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , March 25, 2021 (GLOBE NEWSWIRE) -- Applied Genetics Technologies Corporation
-AGTC will highlight the value of the patient voice in gene therapy development- GAINESVILLE, Fla. and CAMBRIDGE, Mass. , March 18, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , March 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Feb. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
-AGTC executives will address critical success factors in gene therapy manufacturing and the value of the patient perspective in gene therapy development ---- GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Feb. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a
- Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2021 and 2022 - - Net proceeds of approximately $69.2 million from a recent public offering provide cash runway into calendar year 2023 - - Company to host conference call and webcast today at 8:00 a.m.
